Human papillomavirus type 45 L1-specific B-cell receptor (HPV45 L1 BCR) (HPV45 L1 BCR)

Human papillomavirus type 45 (HPV45) L1-specific B-cell receptors (BCRs) and their secreted antibody counterparts are the primary mediators of vaccine-induced immunity against HPV45, a high-risk genotype responsible for approximately 5-6% of cervical cancer cases globally (Sanjose et al., 2010, Lancet Oncology). These receptors are specialized immunoglobulins that recognize the L1 major capsid protein, which self-assembles into virus-like particles (VLPs) used in prophylactic vaccines such as the 9-valent Gardasil 9 (Joura et al., 2015, NEJM). When the L1 antigen binds to these BCRs, it triggers B-cell activation, clonal expansion, and the secretion of high-affinity neutralizing antibodies (Harper & DeAntoni, 2012, Gynecologic Oncology). These antibodies provide protection by sterically hindering the virus's ability to bind to the basement membrane or enter basal keratinocytes. While HPV45 is specifically targeted by the 9-valent vaccine, the bivalent vaccine (Cervarix) also elicits these antibodies through cross-reactivity due to the close genetic relationship between HPV45 and HPV18 (Wheeler et al., 2012, Lancet Infectious Diseases). Monitoring the titers of these antibodies and the frequency of memory B cells is essential for evaluating the long-term duration of protection against HPV45-related malignancies (Dillner et al., 2010, BMJ).

Other names

HPV45 L1 antibodyAnti-HPV45 L1 antibodyHuman papillomavirus 45 L1-specific immunoglobulinAnti-HPV45 L1 BCR

Vaccine-induced activation of B-cell receptors leads to the production of neutralizing antibodies that bind to the HPV45 L1 protein, blocking viral attachment and entry into host cells (Joura et al., 2015, NEJM).